Sandoz, a division of Novartis, and Pear Therapeutics have agreed to jointly commercialize and continue development of novel prescription digital therapeutics designed to treat disease and improve clinical outcomes for patients.
Novartis said that it will invest more than $100m to advance research and development of new antimalarials over the next five years.
Kalytera Therapeutics has announced the termination of its pre-clinical development programs in the treatment of bone disease to focus its resources on graft versus host disease (GVHD) and pain programs.
Inovio Pharmaceuticals has secured funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to develop vaccine candidates against Lassa fever and Middle East Respiratory Syndrome (MERS).
Privately held clinical-stage biotechnology firm Orchard Therapeutics has agreed to acquire the rare disease gene therapy portfolio of GlaxoSmithKline (GSK).
Mylan has acquired an exclusive license to commercialize a biosimilar to Humira (adalimumab), developed by Fujifilm Kyowa Kirin Biologics, in Europe.
Alexion Pharmaceuticals has agreed to acquire Wilson Therapeutics, a Sweden-based company that develops therapies for rare copper-mediated disorders, for SEK7.1bn ($855m).
Mylan has agreed to acquire global marketing rights of Israel-based Mapi Pharma’s GA Depot, a long-acting once-monthly Glatiramer acetate product.
Promethera Biosciences has acquired Baliopharm, a Swiss biopharmaceutical company focused on the development of targeted biological therapies for immune mediated inflammatory diseases and cancer.
AstraZeneca has licensed a fatty liver disease treatment IONIS-AZ6-2.5-LRx (AZD2693) from Ionis Pharmaceuticals in a deal that could fetch up to $300m for the California firm in milestone payments.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.